Longevity & AgingAfib Ablation Gets a Spotlight as Pulsed Field Technology Reshapes Heart Rhythm Treatment
Atrial fibrillation, the most common heart arrhythmia, affects millions and raises risk of stroke, heart failure, and blood clots. Catheter ablation — a minimally invasive procedure targeting the pulmonary veins — is increasingly used as a first-line treatment. A major advance came in 2023 when the FDA approved pulsed field ablation (PFA), which uses high-voltage electrical fields rather than heat or cold to isolate faulty electrical pathways. The 2026 AVANT GUARD trial confirmed PFA reduces arrhythmia recurrence even in harder-to-treat persistent Afib cases. However, early real-world data flagged unique safety concerns including myocardial injury and kidney damage, though newer device designs aim to address these risks. As Afib prevalence rises with age, these evolving treatment options carry direct relevance for older adults managing heart health.
